Literature DB >> 29021106

Use of on-site detoxification services co-located with a supervised injection facility.

Andrew Gaddis1, Mary Clare Kennedy2, Ekaterina Nosova3, M-J Milloy4, Kanna Hayashi5, Evan Wood4, Thomas Kerr6.   

Abstract

OBJECTIVES: Supervised injection facilities (SIFs) are increasingly being implemented worldwide in response to the harms associated with injection drug use. Although SIFs have been shown to promote engagement of people who use injection drugs (PWID) with external health services, little is known about the potential of co-locating on-site detoxification services with SIFs. The aim of this study was to characterize use of detoxification services co-located at Insite, North America's first SIF, among PWID in Vancouver, Canada.
METHODS: Data were derived from two prospective cohorts of PWID in Vancouver, Canada between November 2010 and December 2012. Using multivariable generalized estimating equation logistic regression, we identified factors independently associated with reporting use of detoxification services at the SIF.
RESULTS: Among 1316 PWID, 147 (11.2%) reported enrolling in detoxification services co-located with the SIF at least once during the two year study period. In multivariable analyses, after adjustment for other potential cofounders, factors independently and positively associated with use of this service included residence<5 blocks from the SIF (Adjusted Odds Ratio [AOR]=1.70), enrollment in methadone maintenance therapy (AOR=1.90), public injection (AOR=1.53), binge injection (AOR=1.93), recent overdose (AOR=1.90) and frequent SIF use (AOR=8.15) (all p<0.05). DISCUSSION: Use of on-site detoxification services offered at the SIF was common among PWID and associated with frequent SIF use and various markers of vulnerability and drug-related risk. These findings highlight the potential role of SIFs as a point of access to detoxification services for high-risk PWID. Future studies should examine if co-location leads to higher uptake of addiction services in comparison to services that create geographic or other obstacles.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Detoxification; Drug treatment; Injection drug use; Supervised injection facility

Mesh:

Substances:

Year:  2017        PMID: 29021106      PMCID: PMC5658025          DOI: 10.1016/j.jsat.2017.08.003

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  33 in total

1.  Attendance at supervised injecting facilities and use of detoxification services.

Authors:  Evan Wood; Mark W Tyndall; Ruth Zhang; Jo-Anne Stoltz; Calvin Lai; Julio S G Montaner; Thomas Kerr
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

2.  Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study.

Authors:  Thomas Kerr; Jo-Anne Stoltz; Mark Tyndall; Kathy Li; Ruth Zhang; Julio Montaner; Evan Wood
Journal:  BMJ       Date:  2006-01-28

3.  Inability to access addiction treatment and risk of HIV infection among injection drug users recruited from a supervised injection facility.

Authors:  M-J S Milloy; Thomas Kerr; Ruth Zhang; Mark Tyndall; Julio Montaner; Evan Wood
Journal:  J Public Health (Oxf)       Date:  2009-09-23       Impact factor: 2.341

4.  Impact of length of injecting career on HIV incidence among people who inject drugs.

Authors:  Jacqueline Montain; Lianping Ti; Kanna Hayashi; Paul Nguyen; Evan Wood; Thomas Kerr
Journal:  Addict Behav       Date:  2016-02-16       Impact factor: 3.913

5.  Do supervised injecting facilities attract higher-risk injection drug users?

Authors:  Evan Wood; Mark W Tyndall; Kathy Li; Elisa Lloyd-Smith; Will Small; Julio S G Montaner; Thomas Kerr
Journal:  Am J Prev Med       Date:  2005-08       Impact factor: 5.043

6.  DETERMINANTS OF CUTANEOUS INJECTION-RELATED INFECTIONS AMONG INJECTION DRUG USERS AT AN EMERGENCY DEPARTMENT.

Authors:  Elisa Lloyd-Smith; Mark Tyndall; Ruth Zhang; Eric Grafstein; Sam Sheps; Evan Wood; Julio Montaner; Thomas Kerr
Journal:  Open Infect Dis J       Date:  2012-01

7.  Community-associated methicillin-resistant Staphylococcus aureus is prevalent in wounds of community-based injection drug users.

Authors:  E Lloyd-Smith; M W Hull; M W Tyndall; R Zhang; E Wood; J S G Montaner; T Kerr; M G Romney
Journal:  Epidemiol Infect       Date:  2010-03-05       Impact factor: 2.451

8.  A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver's safer injection facility.

Authors:  Thomas Kerr; Will Small; David Moore; Evan Wood
Journal:  Int J Drug Policy       Date:  2007-01-16

9.  A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada.

Authors:  Ehsan Jozaghi; Andrew A Reid; Martin A Andresen
Journal:  Subst Abuse Treat Prev Policy       Date:  2013-07-09

10.  A cross-sectional national survey assessing self-reported drug intake behavior, contact with the primary sector and drug treatment among service users of Danish drug consumption rooms.

Authors:  Eva Charlotte Toth; Jette Tegner; Sigurd Lauridsen; Nanna Kappel
Journal:  Harm Reduct J       Date:  2016-10-07
View more
  11 in total

1.  How Clinicians Caring for Youth Can Address the Opioid-Related Overdose Crisis.

Authors:  Scott E Hadland
Journal:  J Adolesc Health       Date:  2019-08       Impact factor: 5.012

2.  Health impacts of a scale-up of supervised injection services in a Canadian setting: an interrupted time series analysis.

Authors:  Mary Clare Kennedy; Kanna Hayashi; M-J Milloy; Miranda Compton; Thomas Kerr
Journal:  Addiction       Date:  2021-12-02       Impact factor: 6.526

3.  Supervised Injection Facility Utilization Patterns: A Prospective Cohort Study in Vancouver, Canada.

Authors:  Mary Clare Kennedy; David C Klassen; Huiru Dong; M-J S Milloy; Kanna Hayashi; Thomas H Kerr
Journal:  Am J Prev Med       Date:  2019-08-01       Impact factor: 5.043

4.  Supervised injection facility use and exposure to violence among a cohort of people who inject drugs: A gender-based analysis.

Authors:  Mary Clare Kennedy; Kanna Hayashi; M-J Milloy; Jade Boyd; Evan Wood; Thomas Kerr
Journal:  Int J Drug Policy       Date:  2020-03-19

5.  Assisted injection within supervised injection services: Uptake and client characteristics among people who require help injecting in a Canadian setting.

Authors:  Mary Clare Kennedy; M-J Milloy; Kanna Hayashi; Elizabeth Holliday; Evan Wood; Thomas Kerr
Journal:  Int J Drug Policy       Date:  2020-10-08

6.  Acceptability of safe drug consumption spaces among people who inject drugs in rural West Virginia.

Authors:  Allison O'Rourke; Rebecca Hamilton White; Ju Nyeong Park; Kayla Rodriguez; Michael E Kilkenny; Susan G Sherman; Sean T Allen
Journal:  Harm Reduct J       Date:  2019-08-31

7.  "Beyond Safer Injecting"-Health and Social Needs and Acceptance of Support among Clients of a Supervised Injecting Facility.

Authors:  Vendula Belackova; Edmund Silins; Allison M Salmon; Marianne Jauncey; Carolyn A Day
Journal:  Int J Environ Res Public Health       Date:  2019-06-07       Impact factor: 3.390

8.  Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.

Authors:  Paxton Bach; Daniel Hartung
Journal:  Addict Sci Clin Pract       Date:  2019-09-02

9.  Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study.

Authors:  Mary Clare Kennedy; Kanna Hayashi; M-J Milloy; Evan Wood; Thomas Kerr
Journal:  PLoS Med       Date:  2019-11-26       Impact factor: 11.069

10.  Feasibility, acceptability, concerns, and challenges of implementing supervised injection services at a specialty HIV hospital in Toronto, Canada: perspectives of people living with HIV.

Authors:  Katherine Rudzinski; Jessica Xavier; Adrian Guta; Soo Chan Carusone; Kenneth King; J Craig Phillips; Sarah Switzer; Bill O'Leary; Rosalind Baltzer Turje; Scott Harrison; Karen de Prinse; Joanne Simons; Carol Strike
Journal:  BMC Public Health       Date:  2021-07-29       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.